A Study of the Efficacy and Safety of 24 Week Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Richard Haas, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSD
- Richard Haas, MD
Recall Hcomp, Neurosciences, Vc-health Sciences-schools. Authored (or co-authored) 5 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Reneo Pharma Ltd
- ID
- NCT04535609
- Phase
- Phase 2 Myopathy Research Study
- Study Type
- Interventional
- Participants
- Expecting 200 study participants
- Last Updated